Structure Therapeutics (GPCR) is trading down at $27.59 (-0.29%), as of the latest quote. It operates in the Health Care sector.
| FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| Operating income | −$52.6M | −$102.8M | −$158.2M | −$176.6M |
| Net income | −$51.3M | −$89.6M | −$122.5M | −$141.2M |
| EPS (diluted) | −$5.51 | −$0.81 | −$0.78 | −$0.80 |
| Balance sheet | ||||
| Cash and equivalents | $26.1M | $129.8M | $169.5M | $799.6M |
| Total assets | $97.8M | $482.0M | $903.3M | $1.58B |
| Total liabilities | $13.0M | $29.1M | $38.5M | $67.5M |
| Shareholders' equity | −$115.1M | $453.0M | $864.8M | $1.52B |
| Cash flow | ||||
| Operating cash flow | −$46.1M | −$79.5M | −$116.6M | −$222.2M |
| Capital expenditure | $155.0K | $2.17M | $1.29M | $3.61M |
| Free cash flow | −$46.3M | −$81.7M | −$117.9M | −$225.8M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$45.8M | −$47.1M | −$56.3M | −$70.5M | −$73.8M | $24.0M | −$89.4M | −$118.6M |
| Net income | −$34.0M | −$36.5M | −$46.8M | −$61.7M | −$65.7M | $33.0M | −$76.0M | −$106.2M |
| EPS (diluted) | −$0.20 | −$0.21 | −$0.27 | −$0.36 | −$0.37 | $0.20 | −$0.35 | −$0.49 |
| Balance sheet | ||||||||
| Cash and equivalents | $172.1M | $169.5M | $152.1M | $147.0M | $102.9M | $799.6M | $316.2M | $272.6M |
| Total assets | $933.2M | $903.3M | $866.5M | $816.4M | $832.2M | $1.58B | $1.51B | $1.43B |
| Total liabilities | $36.4M | $38.5M | $41.9M | $44.4M | $62.1M | $67.5M | $61.0M | $71.0M |
| Shareholders' equity | $896.8M | $864.8M | $824.6M | $772.1M | $770.0M | $1.52B | $1.45B | $1.35B |
| Cash flow | ||||||||
| Operating cash flow | −$19.7M | −$36.5M | −$52.2M | −$54.6M | −$51.0M | −$64.4M | $15.2M | −$120.1M |
| Capital expenditure | $685.0K | $16.0K | $314.0K | $232.0K | $1.57M | $1.50M | $1.18M | −$42.0K |
| Free cash flow | −$20.4M | −$36.5M | −$52.5M | −$54.8M | −$52.6M | −$65.9M | $14.1M | −$120.1M |
From Structure Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Structure Therapeutics in our feed yet.